drugset
drugset / Trial / NCT01134016

Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects

NCT01134016 ↗

Phase 1 Completed 13 enrolled Golden Biotechnology Corporation PharmaNet · collab
NaSingle-groupOpen-labelTreatment

Summary

A phase I study to determine the maximum tolerable dose (MTD) and to evaluate pharmacokinetic, safety/tolerability and efficacy profiles of antroquinonol (Hocena®) in non-small cell lung cancer (NSCLC) subjects refractory to conventional treatment modalities

Timeline

Start
2010-12
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Antroquinonol Small molecule 50 mg Oral
Subject Antroquinonol Small molecule 100 mg Oral
Subject Antroquinonol Small molecule 200 mg Oral
Subject Antroquinonol Small molecule 300 mg Oral
Subject Antroquinonol Small molecule 450 mg Oral
Subject Antroquinonol Small molecule 600 mg Oral

Indications

non-small cell lung carcinoma